GLP-1. GIP. Amylin. Incretins. Peptides. NuSH.

It’s not hard to see why the language surrounding modern obesity research sometimes feels like an alphabet soup of scientific terms. But behind each is a growing understanding of how the body regulates hunger, metabolism, energy use, and weight. It’s shaping what we know about how those systems might contribute to obesity.

Recent research suggests that more than 1 billion people worldwide are now living with obesity, and that number is estimated to rise to nearly three billion adults living with obesity or overweight by 2030.1 In the past, many attributed obesity simply to “eating too much” or a lack of willpower. As researchers better understand the condition, however, obesity is increasingly viewed as a chronic metabolic disease influenced by biology, genetics, hormones, brain signaling, and environmental factors. That shift is helping fuel a new wave of therapies designed to target the biological drivers of obesity in more precise ways.

“People haven’t always seen obesity as a disease,” says Dr. William Esler, research project leader at Pfizer. “I think the fact that people are being treated successfully is finally making the connection that this is actually a disorder that can be better managed with medicine.”

Key takeaways

  • Obesity is now widely understood as a chronic metabolic disease shaped by biology, genetics, hormones, and environment. It’s not simply a matter of willpower.
  • The body regulates weight through complex communication between the brain, gut, pancreas, hormones, and fat tissue, involving signaling molecules such as GLP-1, GIP, amylin, and other nutrient-stimulated hormones (NuSH).
  • A biological “set point” is thought to lead the body to defend a certain weight, which helps explain why long-term weight loss is difficult to maintain.
  • Modern obesity therapies are designed to target specific biological pathways. Newer approaches combine multiple mechanisms (such as GLP-1/GIP and GLP-1/amylin dual agonists) to address obesity from more than one angle.
  • Like other chronic conditions, obesity often requires long-term treatment. Stopping weight-loss medication can allow the body to return toward its prior weight.

Understanding the body’s weight regulation system

For decades, obesity was framed as a simple imbalance between calories consumed and calories burned. Nutrition and physical activity are still important, but researchers now recognize that the body has sophisticated systems designed to control appetite, fullness, blood sugar, fat storage, and energy expenditure. These systems involve constant communication between the brain, digestive system, pancreas, hormones, and fat tissue.2

“The hypothalamus and hindbrain play an important role,” Dr. Danna Breen, research fellow at Pfizer, explains. “Neurons in these brain regions sense hormones such as leptin, insulin and gut hormones, which reflect nutrient status. These neurons can then send signals to additional areas of the brain involved in eating behavior and energy expenditure.”

That communication network, also known as the gut-brain axis, helps regulate hunger and feelings of fullness after eating. In people living with obesity, some of those signaling systems may become disrupted, making it harder for the body to regulate weight naturally.3

Why obesity is biologically difficult to overcome

One of the biggest shifts in obesity science has been recognizing why long-term weight loss can be so difficult to maintain. Researchers increasingly point to the body’s internal “set point” system, or the biological mechanisms that are believed to defend a certain body weight.4

When people lose weight, the body may respond by increasing hunger signals, slowing metabolism, or altering hormone levels in ways that encourage weight regain.

“Your body really tries to push you very hard to maintain your set-point weight,” says Dr. Esler. “That’s why people can lose weight but struggle to keep it off.”

Researchers believe hormones such as leptin and insulin may play important roles in this process. In some people, the brain may become resistant to these signals, which in turn prevents the body from accurately sensing fullness or energy stores.4

“It’s very similar to temperature regulation,” Dr. Breen explains. “If you move outside your body’s normal range, your body compensates to get you back there.”

Obesity is more than body size

Thanks to changing attitudes, obesity treatment isn’t simply about appearance. Obesity is associated with over 200 comorbidities and serious health conditions, including:5

  • Cardiovascular disease
  • Certain cancers
  • Fatty liver disease
  • Hypertension
  • Osteoarthritis
  • Sleep apnea
  • Type 2 diabetes

“When we think about treating obesity, it’s not just about the cosmetic aspect,” Dr. Esler says. “It’s really to ameliorate the downstream medical consequences of obesity.” Research has shown that meaningful weight loss can improve or reduce many obesity-related conditions, particularly metabolic diseases such as type 2 diabetes and cardiovascular disease.5

The importance of long-term treatment

As more people use new obesity treatments, researchers stress that these medications aren’t intended for short-term use. “If you stop taking these medicines, your body will defend its weight and try to push you right back to where you were,” Dr. Esler says.

Dr. Breen compares weight-management medications to treatments for other chronic diseases. “Why would you stop taking your blood pressure medication and expect your blood pressure to stay low?” she says. “These are lifelong therapies for many patients.”

But like all medications, obesity therapies carry risks and may cause side effects. The most common side effects associated with GLP-1 treatments are gastrointestinal symptoms, including nausea, vomiting, diarrhea, and constipation.6 Researchers are actively studying ways to improve tolerability through longer-acting formulations, adjusted dosing schedules, and combination approaches.

The future of obesity treatment

Researchers believe today’s therapies are only the beginning. “We’re not done finding novel mechanisms involved in obesity,” Dr. Esler says. “Current incretin-based therapies are life-changing breakthrough medications, but we still need to keep looking for other ways to attack this disease.”

Future obesity treatments may include oral medications, monthly therapies, multi-pathway combinations, and more personalized approaches based on an individual’s metabolic profile. As understanding of obesity biology continues to evolve, researchers hope the conversation around obesity will also evolve away from stigma and toward a more accurate understanding of the disease.

Among the most closely studied near-term options are dual agonist therapies, which simultaneously activate both the GLP-1 and GIP receptors in a single molecule—an approach that early clinical evidence suggests may produce meaningfully greater weight loss than single-pathway GLP-1 treatments alone.7

“There are different types of obesity with different mechanistic drivers,” Dr. Breen says. “With a suite of therapies targeting different aspects of obesity biology, we can hopefully match the right medicine to the right patient.”